> Chemicals & Drugs > Organic Chemical > Efavirenz

Efavirenz

Q: What are the common usage challenges with Efavirenz?

Some common usage challenges with Efavirenz include potential drug interactions, side effects like dizziness and rash, and issues with adherence due to the once-daily dosing regimen. Patients may also experience central nervous system side effects like vivid dreams or difficulty sleeping. Careful monitoring and management of these challenges is important for optimizing Efavirenz therapy.

Q: How can PubCompare.ai help researchers working with Efavirenz?

PubCompare.ai is an invaluable tool for researchers conducting Efavirenz-focused studies. The platform allows you to screen protocol literature more efficiently and leverage AI to pinpoint critical insights. The AI-driven analysis can highlight key differences in protocol effectiveness, enabling you to choose the best option for reproducibility and accuracy in your Efavirenz research. This helps ensure you identify the most effective protocols related to Efavirenz for your specific research goals.

Q: What are the different variations or types of Efavirenz?

While there is primarily one form of Efavirenz, there are some important variations to be aware of. Efavirenz is typically prescribed as part of a fixed-dose combination with other antiretroviral drugs, such as emtricitabine and tenofovir disoproxil fumarate. There are also extended-release formulations of Efavirenz that allow for once-daily dosing. Researchers should familiarize themselves with these different product types and formations when designing Efavirenz studies.

Q: What are some specific applications of Efavirenz?

Efavirenz is primarily used in the treatment of HIV/AIDS, where it has demonstrated efficacy in reducing viral load and improving immune function when used as part of HAART regimens. It may also have potential applications in the treatment of other viral infections, though more research is needed in this area. Some researchers are exploring the use of Efavrenz in novel drug delivery systems or combination therapies to enhance its therapeutic potentical.

Q: Are there any common misspellings or typos associated with Efavirenz?

Yes, one common misspelling or typo associated with Efavirenz is "Efavarinz". This variation can sometimes be seen in medical literature or patient records, so researchers should be aware of it when searching for information or data related to this drug.

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of HIV/AIDS.
It works by blocking the reverse transcriptase enzyme, which is essential for viral replication.
Efavirenz is commonly prescribed in combination with other antiretroviral drugs as part of highly active antiretroviral therapy (HAART) regimens.
The drug has demonstrated efficacy in reducing viral load and improving immune function in people living with HIV.
Researchers can optimize their Efavirenz studies by leveraging PubCompare.ai, an AI-powered platform that helps identify the most accurate and reproducible protocols from literature, preprints, and patents.
The intuitive comparison tools enhance research outcomes by enabling scientists to locate the best products and methods for their Efavirenz-focused investigations.

Most cited protocols related to «Efavirenz»

Quantifying Inducible HIV Transcripts

Cited 20 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2015

Comparing HIV Antiretroviral Regimens

Cited 19 times

The AIDS Clinical Trials Group Study A5202 is an ongoing phase 3B, randomized, partially blinded study comparing four antiretroviral regimens for the initial treatment of HIV-1 infection. The planned study duration was 96 weeks after enrollment of the last patient. Baseline evaluations included a medical history, physical examination, CD4 cell count, and HIV-1 RNA level. At screening, a genotypic resistance test was required in patients with recent HIV-1 acquisition. Testing for the HLA-B*5701 allele was permitted but not required. Patients were randomly assigned to receive one of four oral once-daily regimens: 600 mg of efavirenz (Sustiva, Bristol-Myers Squibb) or 300 mg of atazanavir (Reyataz, Bristol-Myers Squibb) plus 100 mg of ritonavir (Norvir, Abbott Laboratories) given with either 600 mg of abacavir plus 300 mg of lamivudine (Epzicom, GlaxoSmithKline) or 300 mg of tenofovir DF plus 200 mg of emtricitabine (Truvada, Gilead Sciences). The study was double-blinded with regard to the NRTIs.
Randomization was stratified according to the screening HIV-1 RNA level obtained before study entry (≥100,000 vs. <100,000 copies per milliliter), with the use of a permuted-block design with dynamic balancing according to the main institution. Screening of HIV-1 RNA levels was performed at any laboratory certified under the Clinical Laboratory Improvement Amendments. Study evaluations were completed before entry, at entry, at weeks 4, 8, 16, and 24, and every 12 weeks thereafter for the duration of the study in all patients, regardless of any treatment modification. After screening, the level of HIV-1 RNA was measured (Roche Amplicor Monitor assay, version 1.5) at Johns Hopkins University. At the time of protocol-defined virologic failure, geno-typing for drug resistance was performed at Stanford University; the baseline samples obtained from the patients were genotyped retrospectively.
Abbott Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, and GlaxoSmithKline provided the study medications and had input into the protocol development and review of the manuscript. All the authors participated in the trial design, data analysis, and preparation of the manuscript, and all the authors vouch for the completeness and accuracy of the reported data.

Sax P.E., Tierney C., Collier A.C., Fischl M.A., Mollan K., Peeples L., Godfrey C., Jahed N.C., Myers L., Katzenstein D., Farajallah A., Rooney J.F., Ha B., Woodward W.C., Koletar S.L., Johnson V.A., Geiseler P.J, & Daar E.S. (2009). Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy. The New England journal of medicine, 361(23), 2230-2240.

Publication 2009

abacavir - lamivudine Acquired Immunodeficiency Syndrome Alleles Atazanavir AT protocol Biological Assay CD4+ Cell Counts Clinical Laboratory Services efavirenz Emtricitabine Epzicom HIV-1 HIV Infections Norvir Patients Pharmaceutical Preparations Physical Examination Resistance, Drug Reyataz Ritonavir Sustiva Tenofovir Disoproxil Fumarate Testing, AIDS Treatment Protocols Truvada

Timing of ART in HIV-TB Co-Infection

Cited 18 times

The SAPiT study is a three arm, open-label, randomized controlled trial. After providing written informed consent, qualifying HIV-tuberculosis co-infected patients were randomized to one of three treatment arms in a 1:1:1 ratio in permuted blocks of six or nine with no stratification using sealed envelopes; Arm 1 - ART to be initiated within 4 weeks of starting tuberculosis treatment (early integrated treatment arm), Arm 2 - ART to be initiated within 4 weeks of completing the intensive phase of tuberculosis treatment (late integrated treatment arm) and Arm 3 - ART to be initiated within 4 weeks after completing tuberculosis treatment (sequential treatment arm).
All participants received adherence counselling, cotrimoxazole prophylaxis, and the same once daily ART regimen; didanosine (250mg if weight <60kg and 400mg if weight >60kg), lamivudine (300mg) and efavirenz (600mg). ART adherence was assessed monthly by pill counts (pills issued minus pills returned as a percentage of anticipated pill consumption). Regardless of trial arm assignment, participants could be initiated on ART at any time by PCZCDC clinicians, study clinicians or their personal physicians at their discretion.
Follow-up visits for safety and clinical status monitoring were scheduled monthly for 24 months. Adverse events were graded using the Division of AIDS (NIAID/NIH) Table for Grading Adult and Pediatric Adverse Events, version 1.0, 28 December 2004. CD4+ count using the FACS Calibur flow cytometer (Becton Dickinson, Franklin Lakes NJ, USA), HIV RNA (Roche Cobas Amplicor HIV-1 Monitor v1.5) were performed at screening, randomization and 6 monthly thereafter, while radiological changes and sputum conversion were monitored at screening, end of the intensive phase of tuberculosis treatment, one month before the end of tuberculosis treatment and whenever clinically indicated. Secondary endpoints included tolerability, toxicity, HIV RNA, tuberculosis outcomes and IRIS. IRIS was defined as a paradoxical deterioration in clinical status after ART initiation without another attributable cause.

Abdool Karim S.S., Naidoo K., Grobler A., Padayatchi N., Baxter C., Gray A., Gengiah T., Nair G., Bamber S., Singh A., Khan M., Pienaar J., El-Sadr W., Friedland G, & Karim Q.A. (2010). Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy. The New England journal of medicine, 362(8), 697-706.

Publication 2010

Acquired Immunodeficiency Syndrome Adult CD4+ Cell Counts Contraceptives, Oral Didanosine efavirenz HIV-1 Iris Lamivudine Patients Physicians Safety Sputum Treatment Protocols Trimethoprim-Sulfamethoxazole Combination Tuberculosis X-Rays, Diagnostic

Timing of ART Initiation in HIV-TB Co-infection

Cited 16 times

This was a prospective, open-label, randomized trial in South Africa. A total of 642 ambulatory patients with pulmonary tuberculosis and HIV co-infection, aged 18 years or older, were enrolled after obtaining written informed consent.
Pulmonary tuberculosis was confirmed by acid fast bacilli smear positivity. HIV-infection was confirmed by two rapid HIV tests. All patients had a screening CD4+ count < 500 cells/mm³ and were initiated on a standard tuberculosis treatment regimen^{7 (link)}. All first episode tuberculosis patients were treated a fixed drug combination of rifampicin, isoniazid, ethambutol and pyrazinamide dosed according to pre-treatment weight for 2 months (intensive phase) with subsequent fixed-drug combination of isoniazid and rifampicin for 4 months (continuation phase) for all first episodes of tuberculosis. Patients with re-treatment tuberculosis received a 60 day intensive phase which includes streptomycin, followed by a 100 day continuation phase.
Details of the study methods have been previously reported ^{1 (link)}. The once daily antiretroviral therapy regimen contained enteric-coated didanosine (250mg if weight <60kg and 400mg if weight ≥60kg), lamivudine (300mg) and efavirenz (600mg). Antiretroviral therapy adherence was assessed monthly by pill counts. Notwithstanding their study group assignment, patients could be initiated on antiretroviral therapy at any time at the discretion of the study clinicians or their personal physicians.
The outcome of the sequential therapy group has been previously reported^{1 (link)}. This analysis comprises complete follow-up data on the 214 patients in the early integrated-therapy group (antiretroviral therapy to be initiated within 4 weeks of starting tuberculosis treatment) and the 215 patients in the late integrated-therapy group (antiretroviral therapy to be initiated within 4 weeks of completing the intensive phase of tuberculosis treatment). The details of the study methods and data on 18 months follow-up of all three study groups are provided in the supplementary appendix (Supplementary Tables 1–3).
All analyses were by intention-to-treat. The trial’s primary outcome, AIDS or death rate, was analyzed using Kaplan–Meier curves. The duration of time in the study was calculated as the time from randomization to death or AIDS-defining illness, withdrawal from the study, or 18 months post randomization, whichever occurred first. Poisson approximations were used to calculate confidence intervals for the incidence rate ratios. Proportional-hazards regression was used to adjust for confounding variables. Fisher’s exact test was used for the analysis of categorical data, and unpaired t-tests or the Wilcoxon two-sample test for the analysis of continuous data. Interactions between therapy group and CD4+ count were evaluated by fitting a proportional hazards model with therapy group, CD4+ count and their interaction.
The trial (NCT00398996) was approved by the University of KwaZulu-Natal’s Biomedical Research Ethics Committee (E 107/05) and the Medicines Control Council (MCC ref: 20060157). Study data were reviewed periodically by a Safety Monitoring Committee.

Abdool Karim S.S., Naidoo K., Grobler A., Padayatchi N., Baxter C., Gray A.L., Gengiah T., Gengiah S., Naidoo A., Jithoo N., Nair G., El-Sadr W.M., Friedland G, & Abdool Karim Q. (2011). Integration of Antiretroviral Therapy with Tuberculosis Treatment. The New England journal of medicine, 365(16), 1492-1501.

Publication 2011

Acquired Immunodeficiency Syndrome Bacillus acidicola CD4+ Cell Counts Cells Contraceptives, Oral Didanosine Drug Combinations efavirenz Ethambutol Ethics Committees, Research Group Therapy HIV Infections Isoniazid Lamivudine Patients Pharmaceutical Preparations Physicians Pyrazinamide Rifampin Safety Streptomycin Testing, AIDS Therapeutics Treatment Protocols Tuberculosis Tuberculosis, Pulmonary

Hair-Based Antiretroviral Quantification

Cited 15 times

Efavirenz, lopinavir and ritonavir reference compounds, and internal standards (IS), ritonavir-d6 and celecoxib, were obtained from Toronto Research Chemicals (Toronto, Canada). Proteinase K was purchased from Sigma^™. Acetonitrile, methanol and other solvents or reagents were HPLC grade or analytical grade. Human hair samples were obtained from patients on lopinavir/ritonavir or efavirenz–based HAART in the Women’s Interagency HIV Study (WIHS). Blank human hair samples were obtained from healthy volunteers to serve as negative controls.

Huang Y., Gandhi M., Greenblatt R.M., Gee W., Lin E.T, & Messenkoff N. (2008). Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. Rapid communications in mass spectrometry : RCM, 22(21), 3401-3409.

Publication 2008

acetonitrile Antiretroviral Therapy, Highly Active Celecoxib efavirenz Endopeptidase K Hair Healthy Volunteers High-Performance Liquid Chromatographies Homo sapiens Lopinavir lopinavir-ritonavir drug combination Methanol Patients Ritonavir Solvents Woman

Most recents protocols related to «Efavirenz»

PBPK Model Predicts Brigatinib Interactions

The verified PBPK model was subsequently applied to predict changes in brigatinib systemic exposures following co‐administration with the moderate CYP3A inhibitors diltiazem and verapamil, and the moderate CYP3A inducer efavirenz. For each simulation scenario, 10 virtual trials of 20 healthy participants (30% women; aged 23–60 years) were performed. For the moderate CYP3A inhibitor simulations, brigatinib concentrations were predicted following a single dose of 90 mg brigatinib alone and then following co‐administration on the eighth day of 15 days of dosing with diltiazem (60 mg 3 times a day [t.i.d.]) or verapamil (120 mg t.i.d.). Similarly, the efavirenz simulation predicted brigatinib concentrations following a single dose of brigatinib 90 mg in the absence of efavirenz and then following co‐administration on the eighth day of 15 days of dosing with efavirenz 600 mg q.d. The default Simcyp compound library files for diltiazem, verapamil, and efavirenz were used in the simulations.

Hanley M.J., Yeo K.R., Tugnait M., Iwasaki S., Narasimhan N., Zhang P., Venkatakrishnan K, & Gupta N. (2024). Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach. CPT: Pharmacometrics & Systems Pharmacology, 13(4), 624-637.

Publication 2024

Comprehensive Pharmacokinetic Profiling Protocol

Psilocin was purchased from Lipomed (Arlesheim, Switzerland), while 4-HIAA and 4-HTP were synthesized by ReseaChem (Burgdorf, Switzerland). The purity of all aforementioned analytes was >98%.
CYP substrates including tizanidine hydrochloride (CYP1A2) (S)-efavirenz (CYP2B6), paclitaxel (CYP2C8), flurbiprofen (CYP2C9), omeprazole (CYP2C19), and metoprolol (CYP2D6) were obtained from Toronto Research Chemicals (TRC; Toronto, Canada). CYP3A4 substrate midazolam was acquired from Lipomed, while chlorzoxazone (CYP2E1) was purchased from Sigma-Aldrich. Metabolites including hydroxy-tizanidine (OH-tizanidine; CYP1A2), 8-hydroxy-efavirenz (OH-efavirenz; CYP2B6), 6-α-hydroxy-paclitaxel (OH-paclitaxel; CYP2C8), 4-hydroxy-flurbiprofen (OH-flurbiprofen; CYP2C9), 5-hydroxy-omeprazole (OH-omeprazole; CYP2C19), α-hydroxy-metoprolol (OH-metoprolol; CYP2D6), and 6-hydroxy-chlorzoxazone (OH-chlorzoxazone; CYP2E1) were all purchased from TRC, while α-hydroxy-midazolam (OH-midazolam; CYP3A4) was obtained from Lipomed.
CYP inhibitors ticlopidine hydrochloride (CYP2B6), sulfaphenazole (CYP2C9) (+)-N-3-benzylnirvanol (CYP2C19), quinidine sulfate (CYP2D6), 4-methylpyrazole hydrochloride (CYP2E1), and ketoconazole (CYP3A4) were all purchased from Sigma-Aldrich. Furafylline (CYP1A2) was purchased from TRC while montelukast dicyclohexylamine (CYP2C8) was obtained from the European Directorate for the Quality of Medicines and Healthcare (Strasbourg, France).
The MAO-A and MAO-B substrate kynuramine dihydrobromide, its metabolite 4-hydroxyquinoline (4-HQ), and inhibitors clorgyline hydrochloride (MAO-A) and R-deprenyl hydrochloride (MAO-B) were all purchased from Sigma-Aldrich. N,N-dimethyltryptamine (DMT) and its metabolite indole-3-acetic acid (IAA) monosodium salt were acquired from Lipomed and Cayman Chemical (Ann Arbor, USA), respectively.
Internal standards (ISTD) psilocin-d₁₀ and IAA-d₂ were acquired from Sigma-Aldrich, while L-tryptophan-d₅, tizanidine-d₄, efavirenz-d₅, paclitaxel-d₅, flurbiprofen-d₃, omeprazole-d₃, metoprolol-d₆, chlorzoxazone-d₃, and midazolam-d₆ were obtained from TRC. DMT-d₆ was purchased from ReseaChem.

Thomann J., Kolaczynska K.E., Stoeckmann O.V., Rudin D., Vizeli P., Hoener M.C., Pryce C.R., Vollenweider F.X., Liechti M.E, & Duthaler U. (2024). In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin. Frontiers in Pharmacology, 15, 1391689.

Full text: Click here

Publication 2024

Urine and DBS Biomarkers for Viremia in HIV Patients

We conducted a cross-sectional analysis at enrolment into a randomised study of point-of-care HIV viral load testing (POwER) [12 ]. We included consecutively enrolled POwER participants receiving TDF as part of dolutegravir or efavirenz-based first-line ART. Eligible PWH had a preenrolment viral load greater than 1000 copies/ml in the past 6 weeks, without having received enhanced adherence counselling. At enrolment, participants self-reported adherence, and had urine, DBS and plasma samples taken and stored at −80 °C, for retrospective testing.
We quantitated urine TFV and DBS TFV-DP concentrations using liquid chromatography and dual tandem mass spectrometry (LC-MS/MS). We tested viral load using the cobas 6800 platform (Roche, Basel, Switzerland), and attempted drug resistance testing for all samples with viral load at least 1000 copies/ml (see testing details supplement).
We used logistic regression models to assess the relationship between the exposure of either urine TFV concentrations, or DBS TFV-DP concentrations, and the outcome of viraemia. To determine whether associations differed by ART regimen, we included a variable for ART regimen (dolutegravir versus efavirenz) in the model, with an interaction term between ART regimen and urine TFV, or DBS TFV-DP concentrations. We fitted separate models for the outcomes of viraemia at least 1000 copies/ml, and at least 50 copies/ml, as these thresholds are used in WHO guidelines [1 ]. We compared the Nagelkerke pseudo-R² of the urine TFV and DBS TFV-DP models to determine which measure was more strongly associated with viraemia [13 ]. In exploratory, post hoc analyses, we used receiver-operating curves (ROCs) to estimate urine TFV and DBS TFV-DP thresholds that maximize sensitivity and specificity to predict concurrent viraemia. Lastly, we described urine TFV and DBS TFV-DP levels among people with and without HIVDR, and compared self-reported short-term and longer term adherence with urine TFV and DBS TFV-DP levels using logistic regression and linear regression models, respectively. Sample size was determined by the number of participants enrolled into POwER and receiving TDF.
We analysed data using R 4.2.0 (R Foundation for Statistical Computing, Vienna, Austria). The University of KwaZulu-Natal Biomedical Research Ethics Committee (BREC 00000836/2019) and the University of Oxford Tropical Research Ethics Committee (OxTREC 66-19) approved the study.

Dorward J., Govender K., Moodley P., Lessells R., Samsunder N., Sookrajh Y., Fanshawe T.R., Turner P.J., Butler C.C., Drain P.K., Hayward G.N, & Garrett N. (2024). Urine tenofovir and dried blood spot tenofovir diphosphate concentrations and viraemia in people taking efavirenz and dolutegravir-based antiretroviral therapy. AIDS (London, England), 38(5), 697-702.

Full text: Click here

Publication 2024

Quantitative Bioanalysis of Drugs in Plasma

Midazolam and stable isotope-labeled internal standard (SLIS) midazolam-D4 were isolated from K₂EDTA human plasma using a liquid-liquid extraction procedure. Following extraction and processing, samples were analyzed by high‐performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) using a Waters Xbridge HILIC, 2.1 × 50 mm, 3.5-µm column under positive mode with a TurboIonSpray interface.
EE and SLIS EE-D₄ were isolated from K₂EDTA human plasma using a liquid-liquid extraction and derivatization procedure. After processing, samples were analyzed by high-performance liquid chromatography (UPLC-MS/MS) using a Zorbax SB-C18, 50 × 4.6 mm, 3.5-µm column under positive mode with a TurboIonSpray interface.
Levonorgestrel and its SLIS levonorgestrel-d₆ were isolated from K₂EDTA human plasma using an automated liquid-liquid extraction procedure. After processing, the samples were injected into LC-MS/MS using a Chromolith/Speed Rod, 50 × 4.6 mm, 2-μm column under positive mode with a TurboIonSpray interface.
Caffeine and its SLIS caffeine-D₉ were isolated from K₂EDTA human plasma using an automated protein precipitation extraction procedure. After processing, the samples were injected into LC-MS/MS using an ACE 3 C18-PFP, 50 × 4.6 mm, 3-μm column under positive mode with a TurboIonSpray interface.
Omeprazole and its SLIS omeprazole-D₃ were isolated from K₂EDTA human plasma using an automated protein precipitation extraction procedure. After processing, the samples were injected into LC-MS/MS using an Acquity UPLC BEH C18, 100 × 2.1 mm, 1.7-μm column under positive mode with a TurboIonSpray interface.
Unconjugated efavirenz (referred to as efavirenz from here on) and SLIS efavirenz-D₅ were extracted from K₂EDTA plasma by an automated liquid-liquid extraction procedure. After processing, the samples were injected into LC-MS/MS using an ACE Excel 2 C18, 50 × 3 mm, 2-μm column under negative mode with a TurboIonSpray interface.

Wang X., Dowty M.E., Tripathy S., Le V.H., Huh Y., Curto M., Winton J.A., O’Gorman M.T., Chan G, & Malhotra B.K. (2024). Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy Individuals. European Journal of Drug Metabolism and Pharmacokinetics, 49(3), 367-381.

Publication 2024

Preparation of Oriented Chiral Samples

Not available on PMC !

Chemicals and preparation of oriented samples (R)-Flurbiprofen was purchased at Acros Organics with a purity of 97%. rac-Flurbiprofen was purchased at Sigma-Aldrich (Merck) with a purity of 98%. (S)-Efavirenz was purchased at TCI with a purity of 98%. rac-Efavirenz was purchased at Toronto Research Chemical (TRC) with a purity of 97%. The PBLG polymer (Lot SLBZ3570 with a degree of polymerization DP = 849) was purchased at Aldrich (Merck). All compounds were used with any further purification.
The oriented samples were prepared directly in the NMR tube by mixing the chiral analyte (<30 mg), the PBLG (nearby 100 mg) and the organic co-solvent (CHCl 3 ). The amount of chloroform (about 600 mg) was here adjusted so that the total weight% of PBLG (i.e., mass of PBLG/total mass) was maintained at around 14%, and the sample length reached 4 cm. The exact sample compositions are given in Table SI-1 in ESI. † The 5 mm NMR tube was then fire-sealed to avoid CHCl 3 evaporation over time and several low-speed centrifugation cycles of the sample (e.g., 500 rpm during 20 s) were carried out to remove matter gradients. The tube was inverted between each centrifugation.

Gouilleux B., Moussallieh F.M, & Lesot P. (2024). Potential and performance of anisotropic ¹⁹F NMR for the enantiomeric analysis of fluorinated chiral active pharmaceutical ingredients. The Analyst, 149(11).

Publication 2024

Top products related to «Efavirenz»

Efavirenz by Merck Group

Sourced in Switzerland, United States

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used as a component of antiretroviral therapy for the treatment of HIV-1 infection. It functions by binding to and inhibiting the HIV-1 reverse transcriptase enzyme, thereby preventing the replication of the virus.

Sas version 9 by SAS Institute

Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India

SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.

Dimethyl sulfoxide (dmso) by Merck Group

Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh

DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.

Formic acid by Merck Group

Sourced in Germany, United States, Italy, United Kingdom, France, Spain, China, Poland, India, Switzerland, Sao Tome and Principe, Belgium, Australia, Canada, Ireland, Macao, Hungary, Czechia, Netherlands, Portugal, Brazil, Singapore, Austria, Mexico, Chile, Sweden, Bulgaria, Denmark, Malaysia, Norway, New Zealand, Japan, Romania, Finland, Indonesia

Formic acid is a colorless, pungent-smelling liquid chemical compound. It is the simplest carboxylic acid, with the chemical formula HCOOH. Formic acid is widely used in various industrial and laboratory applications.

Sas 9 by SAS Institute

Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia

SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.

Prism 8 by GraphPad

Sourced in United States, Austria, Canada, Belgium, United Kingdom, Germany, China, Japan, Poland, Israel, Switzerland, New Zealand, Australia, Spain, Sweden

Prism 8 is a data analysis and graphing software developed by GraphPad. It is designed for researchers to visualize, analyze, and present scientific data.

Efavirenz by Selleck Chemicals

Efavirenz is a laboratory chemical compound used in the research and development of pharmaceutical products. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that can be utilized in the study of HIV/AIDS treatments. The core function of Efavirenz is to serve as a research tool for scientists and researchers working in the field of antiviral drug development.

Facscalibur by BD

Sourced in United States, Germany, United Kingdom, China, Canada, Japan, Italy, France, Belgium, Switzerland, Singapore, Uruguay, Australia, Spain, Poland, India, Austria, Denmark, Netherlands, Jersey, Finland, Sweden

The FACSCalibur is a flow cytometry system designed for multi-parameter analysis of cells and other particles. It features a blue (488 nm) and a red (635 nm) laser for excitation of fluorescent dyes. The instrument is capable of detecting forward scatter, side scatter, and up to four fluorescent parameters simultaneously.

Qiaamp dna mini kit by Qiagen

Sourced in Germany, United States, France, United Kingdom, Netherlands, Spain, Japan, China, Italy, Canada, Switzerland, Australia, Sweden, India, Belgium, Brazil, Denmark

The QIAamp DNA Mini Kit is a laboratory equipment product designed for the purification of genomic DNA from a variety of sample types. It utilizes a silica-membrane-based technology to efficiently capture and purify DNA, which can then be used for various downstream applications.

Nevirapine by Merck Group

Sourced in United States, United Kingdom

Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of HIV-1 infection. It is a laboratory product manufactured by Merck Group for research purposes.

What are the common usage challenges with Efavirenz?

Some common usage challenges with Efavirenz include potential drug interactions, side effects like dizziness and rash, and issues with adherence due to the once-daily dosing regimen. Patients may also experience central nervous system side effects like vivid dreams or difficulty sleeping. Careful monitoring and management of these challenges is important for optimizing Efavirenz therapy.

How can PubCompare.ai help researchers working with Efavirenz?

PubCompare.ai is an invaluable tool for researchers conducting Efavirenz-focused studies. The platform allows you to screen protocol literature more efficiently and leverage AI to pinpoint critical insights. The AI-driven analysis can highlight key differences in protocol effectiveness, enabling you to choose the best option for reproducibility and accuracy in your Efavirenz research. This helps ensure you identify the most effective protocols related to Efavirenz for your specific research goals.

What are the different variations or types of Efavirenz?

While there is primarily one form of Efavirenz, there are some important variations to be aware of. Efavirenz is typically prescribed as part of a fixed-dose combination with other antiretroviral drugs, such as emtricitabine and tenofovir disoproxil fumarate. There are also extended-release formulations of Efavirenz that allow for once-daily dosing. Researchers should familiarize themselves with these different product types and formations when designing Efavirenz studies.

What are some specific applications of Efavirenz?

Efavirenz is primarily used in the treatment of HIV/AIDS, where it has demonstrated efficacy in reducing viral load and improving immune function when used as part of HAART regimens. It may also have potential applications in the treatment of other viral infections, though more research is needed in this area. Some researchers are exploring the use of Efavrenz in novel drug delivery systems or combination therapies to enhance its therapeutic potentical.

Are there any common misspellings or typos associated with Efavirenz?

More about "Efavirenz"

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat HIV/AIDS.
It works by blocking the reverse transcriptase enzyme, which is essential for viral replication.
Efavirenz is commonly prescribed in combination with other antiretroviral drugs as part of highly active antiretroviral therapy (HAART) regimens.
The drug has demonstrated efficacy in reducing viral load and improving immune function in people living with HIV.
To optimize your Efavirenz research, you can leverage the power of PubCompare.ai, an AI-powered platform that helps identify the most accurate and reproducible protocols from literature, preprints, and patents.
The intuitive comparison tools on PubCompare.ai can enhance your research outcomes by enabling you to locate the best products and methods for your Efavirenz-focused investigations.
In addition to Efavirenz, other related terms and substances you may encounter in your research include SAS version 9.4, DMSO, Formic acid, SAS 9.4, Prism 8, FACSCalibur, and the QIAamp DNA Mini Kit.
These tools and reagents can be useful in various aspects of Efavirenz-related studies, such as data analysis, cell culture, flow cytometry, and DNA extraction.
By utilizing the insights gained from the MeSH term description and the Metadescription, and incorporating relevant synonyms, abbreviations, and key subtopics, you can optimize your Efavirenz research and enhance your overall outcomes.
Remember to always double-check your work for any typos or errors, as even the most diligent researchers can occasionally make a mistke.